Reputation Institute Announces Annual Pharma RepTrak Ratings
Reputation Institute (RI), provider of reputation measurement, monitoring, and management services, announced its annual US Pharma RepTrak rankings. The survey looks at 2,608 individual ratings of pharma companies for the first quarter of 2018 and quantifies the emotional bond stakeholders have with pharma companies in the US, and how these connections drive supportive behavior such as the willingness to purchase a company’s products, recommend the brand, invest in or work for a company.
The top 10 companies in RI’s 2018 US Pharma RepTrak are:
1. Sanofi
2. Genentech
3. Celgene
4. AbbVie
5. Biogen
6. Bayer
7. Gilead
8. Allergan
9. Novo Nordisk
10. McKesson
The 2018 US Pharma RepTrak results reveal that national and industry reputations are under stress, with pharmaceutical companies following the broader national trends with a -3.7 point decline in reputation score compared to 2017. RI’s research analyst, Meghan Burke, wrote about this in detail for Pharm Exec’s blog. See her blog post here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
